Reduxin capsules 15mg 30Composition1 caps.sibutramine hydrochloride monohydrate 15 mgcellulose microcrystalline 153.5 mgExcipients: calcium stearate 1.5 mg.The composition of the capsule shell: titanium dioxide 2%, patent blue dye 0.2737%, gelatin up to 100%.Pharmacotherapeutic groupObesity treatment.Indications for useFor weight loss in the following conditions:alimentary obesity with a body mass index (BMI) of 30 kgm2 or more;alimentary obesity with a BMI of 27 kgm2 or more in combination with type 2 diabetes mellitus and dyslipidemia.Mode of applicationReduxin® is prescribed orally 1 time day. The dose is set individually, depending on tolerability and clinical efficacy.The recommended initial dose is 10 mgday, with poor tolerance, a dose of 5 mgday may be taken.Capsules should be taken in the morning without chewing and with a sufficient amount of liquid (a glass of water). The drug can be taken on an empty stomach or combined with food intake.If within 4 weeks from the start of treatment a decrease in body weight of less than 2 kg is not achieved, then the dose is increased to 15 mg day. Treatment with Reduxin® should not last more than 3 months in patients who do not respond well enough to therapy, i.e. who within 3 months of treatment fail to achieve a weight loss of 5% of the baseline. Treatment should not be continued if, during further therapy, after the achieved weight loss, the patient again adds 3 kg or more in body weight. The duration of treatment should not exceed 1 year, since there are no data on efficacy and safety for a longer period of taking sibutramine.Treatment with Reduxin® should be carried out in combination with diet and exercise under the supervision of a physician with practical experience in the treatment of obesity.